default author photo

The GAP Study Group

Independent

United States

SCHOLARLY PAPERS

1

DOWNLOADS

128

TOTAL CITATIONS

1

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Gemcitabine or Abraxane Combined with cisPlatin (GAP) as First-Line Treatment in Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter, Randomized, Open-Label, Phase 3 Trial

Downloads 128 (565,439)
Citation 1

Gemcitabine or Abraxane Combined with cisPlatin (GAP) as First-Line Treatment in Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter, Randomized, Open-Label, Phase 3 Trial

Number of pages: 21 Posted: 10 Nov 2020
Biyun Wang, Tao Sun, Yannan Zhao, Shusen Wang, Jian Zhang, Zhonghua Wang, Yue-E Teng, Li Cai, Min Yan, Xiaojia Wang, Zefei Jiang, Yueyin Pan, Jianfeng Luo, Zhimin Shao, Jiong Wu, Xiaomao Guo, Xi-Chun Hu and The GAP Study Group
Fudan University - Department of Medical Oncology, Liaoning Cancer Hospital & Institute - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Sun Yat-Sen University (SYSU) Cancer Center - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Fudan University - Department of Breast Surgery, China Medical University - Department of Medical Oncology, Harbin Medical University - Department of Medical Oncology, Zhengzhou University - Henan Cancer Hospital, Breast Cancer Center, Zhejiang Cancer Hospital - Department of Medical Oncology, Chinese PLA General Hospital - The Fifth Medical Center, Department of Medical Oncology, Anhui Medical University - Department of Medical Oncology, Fudan University - School of Public Health, Department of Biostatics, Fudan University - Department of Breast Surgery, Fudan University - Department of Breast Surgery, Fudan University - Department of Radiation Oncology, Fudan University - Department of Medical Oncology and Independent
Downloads 66 (921,129)
Citation 1

Abstract:

Loading...

metastatic triple-negative breast cancer, Chemotherapy, cisplatin, nab-paclitaxel

Gemcitabine or Abraxane Combined with cisPlatin (GAP) as First-Line Treatment in Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter, Randomized, Open-Label, Phase 3 Trial

Number of pages: 21 Posted: 12 Oct 2020
Biyun Wang, Tao Sun, Yannan Zhao, Shusen Wang, Jian Zhang, Zhonghua Wang, Yue-E Teng, Li Cai, Min Yan, Xiaojia Wang, Zefei Jiang, Yueyin Pan, Jianfeng Luo, Zhimin Shao, Jiong Wu, Xiaomao Guo, Xi-Chun Hu and The GAP Study Group
Fudan University - Department of Medical Oncology, Liaoning Cancer Hospital & Institute - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Sun Yat-Sen University (SYSU) Cancer Center - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Fudan University - Department of Breast Surgery, China Medical University - Department of Medical Oncology, Harbin Medical University - Department of Medical Oncology, Zhengzhou University - Henan Cancer Hospital, Breast Cancer Center, Zhejiang Cancer Hospital - Department of Medical Oncology, Chinese PLA General Hospital - The Fifth Medical Center, Department of Medical Oncology, Anhui Medical University - Department of Medical Oncology, Fudan University - School of Public Health, Department of Biostatics, Fudan University - Department of Breast Surgery, Fudan University - Department of Breast Surgery, Fudan University - Department of Radiation Oncology, Fudan University - Department of Medical Oncology and Independent
Downloads 62 (957,329)

Abstract:

Loading...

triple-negative breast cancer, chemotherapy, platinum, nab-paclitaxel